Certificate in Cancer Immunotherapy

CP2_-_Copy.png


The Society for Immunotherapy of Cancer (SITC) is pleased to offer physicians and qualified healthcare providers the opportunity to earn a Certificate in Cancer Immunotherapy, supporting their knowledge and skills to provide effective and safe care for patients treated with cancer immunotherapy. Learners can expect to develop a comprehensive understanding of cancer immunotherapies, including checkpoint inhibitors, cell therapies and many others, as well as the management of side effects, allowing them to successfully implement immunotherapy in clinical practice.  

The Certificate in Cancer Immunotherapy consists of eight independent learning modules—all approved for CME, CNE, CPE and MOC credits—that can be stacked to earn the SITC Graduate in Cancer Immunotherapy (SITC-G) designation. The SITC-G designation identifies a healthcare provider as completing specialized training in cancer immunotherapy.  

Learning Modules

  • Module 1: Basic Immunology Conceptsavailable now!
    • This course, Module 1: Basic Immunology Concepts, will cover some of the key immunology needed to understand the rest of the certificate program.
  • Module 2: Basic Cancer Immunotherapy Concepts, available September 2020
    • This course, Module 2: Basic Cancer Immunotherapy Concepts, will cover the biological foundation of cancer immunotherapy, applying the basic immunology you learned in the last module to help lay the foundation for future topics in this program.
  • Module 3: Immune Checkpoint Blockadeavailable October 2020
    • This course, Module 3: Immune Checkpoint Blockade, will cover the biological foundation of immune checkpoint blockade therapies as well as diving into their clinical use.
  • Module 7: CAR T Cell and Cellular Therapy, available February 2021
    • This course, Module 7: CAR T Cell and Cellular Therapy, will cover the mechanisms and clinical administration of cellular therapies for cancer, including an emphasis on adverse event management.
  • Module 8: Implementing Cancer Immunotherapy in Clinical Practice, available March 2021
    • This course, Module 8: Implementing Cancer Immunotherapy in Clinical Practice, will cover the practical aspects of instituting immunotherapy treatments in a clinical practice, such as education considerations, value-based care, and access to patient and provider resources.

Target Audiences

The primary target audience for the program is treating physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate will also be available to practicing, licensed NPs, PAs, and PharmDs (or RPh degree holders involved in direct clinical services), or global equivalent. The courses will be available to those who are not practicing clinicians, but they will not be eligible to earn the certificate.

Requirements

The requirements to earn the certificate include:

  • Complete the coursework (all eight modules)
    • anticipated to be approximately 1.5 hours each, for a total of 12–16 hours
  • Pass all end-of-module assessments
  • Successfully complete a comprehensive exam covering all modules

Certificate Term

The certificate term is two years. Then, to earn a current certificate, which allows one to continue to use the SITC-G designation, an individual will need to take and pass updated coursework and assessments. If one misses the deadline for reissuance, he or she will need to retake and pass the full program.

Designation

SITC Graduate in Cancer Immunotherapy / SITC-G

CP1.png




Cost per Module

SITC Member Price: $25.00
Non-Member Price: $31.25



Learner Notification

Certificate Program Task Force

CHAIR

Robert L. Ferris, MD, PhD
University of Pittsburgh Medical Center Hillman Cancer Center


Members

Leisha Emens, MD, PhD — University of Pittsburgh Medical Center Hillman Cancer Center
Umar Farooq, MD — University of Iowa
Silvia Formenti, MD — Weill Cornell Medicine
Sigrun Hallmeyer, MD — Advocate Lutheran General Hospital
Howard Kaufman, MD, FACS — Immuneering Corporation
Jose Lutzky, MD, FACP — University of Miami, Sylvester Cancer Center
George Weiner, MD — University of Iowa